A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy

Tyrosine kinase inhibitor (TKI) therapies induce clinical remission with remarkable effects on chronic myeloid leukemia (CML). However, very few TKIs completely eradicate the leukemic clone and persistence of leukemic stem cells (LSCs) remains challenging, warranting new, distinct targets for improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, X, Rothe, K, Yen, R, Fruhstorfer, C, Maetzig, T, Chen, M, Forrest, D L, Humphries, R K, Jiang, X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668499/
https://www.ncbi.nlm.nih.gov/pubmed/28366933
http://dx.doi.org/10.1038/leu.2017.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668499/
https://www.ncbi.nlm.nih.gov/pubmed/28366933
http://dx.doi.org/10.1038/leu.2017.108

Ejemplares similares